Herbal Monograph
Saw Palmetto
Serenoa repens (W.Bartram) Small
Arecaceae
The premier botanical for prostate and urinary health -- from Seminole traditional medicine to modern urology clinics worldwide.
Overview
Plant Description
A small, creeping, clump-forming palm with a sprawling or horizontal trunk (rhizome-like stem) typically 1-2 m tall, occasionally reaching 3-4 m. The trunk grows horizontally along the ground or just below the soil surface, branching and forming dense thickets that can cover extensive areas. Leaves are fan-shaped (palmate), 50-100 cm across, with 18-25 stiff, lance-shaped leaflet segments radiating from a central point. Petioles (leaf stalks) are 60-100 cm long, armed along both margins with small, sharp, recurved teeth (the 'saw' of saw palmetto) that can inflict painful lacerations. Leaf color ranges from yellow-green to blue-green or silver-green. Inflorescences are branched panicles arising among the leaves, shorter than the leaf blades, bearing numerous small, fragrant, yellowish-white flowers approximately 5 mm across with 3 petals and 6 stamens. Flowering occurs primarily in April-June. Fruit is a one-seeded drupe (berry-like), ovoid to ellipsoid, 1.5-2.5 cm long, ripening from green through yellow-orange to blue-black (September-November). The mesocarp is oily and fleshy, with a distinctive sweetish, slightly rancid taste and soapy mouthfeel. The endocarp is thin and hard, enclosing a single large seed. Extremely long-lived; individual clones may persist for several hundred years. Fire-adapted species that resprouts vigorously from the rhizomatous trunk after wildfire.
Habitat
Coastal plains, sand pine scrub, pine flatwoods, and mesic hammocks of the southeastern United States. Thrives in sandy, acidic, well-drained soils typical of coastal plain ecosystems. Tolerates nutrient-poor conditions, periodic flooding, drought, and fire. A characteristic understory species of longleaf pine (Pinus palustris) savannas and sand pine (Pinus clausa) scrub communities. Can form dense, nearly impenetrable thickets that dominate the ground layer. Fire-dependent ecology: regular fire prevents overgrowth by hardwoods and maintains open pine-palmetto communities. Grows from sea level to approximately 150 m elevation.
Distribution
Endemic to the southeastern United States, primarily the coastal plain from southeastern South Carolina through Georgia, Florida, southern Alabama, and southern Mississippi. The center of abundance is peninsular Florida, where saw palmetto is one of the most common native plants and dominates millions of hectares of pine flatwoods and scrubland. Isolated populations occur in coastal Louisiana and southeastern Texas. Does not occur naturally outside the southeastern United States. Not successfully cultivated at commercial scale for fruit production; virtually all commercial supply is wild-harvested from native Florida populations.
Parts Used
Ripe berries (fruit / Sabalis serrulatae fructus)
Preferred: Liposterolic (hexane or supercritical CO2) extract, ethanol extract, whole dried berry
The ripe dried fruit is the sole medicinally used plant part. The pharmacopoeial drug consists of the dried, ripe fruit of Serenoa repens. The berries contain the lipophilic constituents (fatty acids, phytosterols, fatty alcohols) responsible for the anti-androgenic and anti-inflammatory activity. Both blue-black and yellow-orange color morphs are used commercially. The European Pharmacopoeia and USP-NF both include monographs for Saw Palmetto Fruit. All clinically studied extracts are derived from the ripe berries.
Key Constituents
Fatty acids (free fatty acids and their glycerides)
Free fatty acids constitute approximately 80-90% of the liposterolic extract and are considered the primary bioactive fraction responsible for 5-alpha-reductase inhibition and anti-androgenic activity. The unique fatty acid profile of saw palmetto, particularly the high proportion of lauric and myristic acids, is distinct from common dietary oils and correlates with anti-prostatic activity. Free fatty acids (non-esterified) demonstrate stronger 5-alpha-reductase inhibition in vitro than their esterified (triglyceride) forms, which is why the liposterolic extraction method that enriches free fatty acids is pharmacologically preferred. The fatty acid fraction also inhibits cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways, contributing to anti-inflammatory activity in prostate tissue.
Phytosterols (plant sterols)
Phytosterols, particularly beta-sitosterol, contribute to the anti-prostatic and anti-inflammatory activity of saw palmetto. Wilt et al. (1999) Cochrane review of beta-sitosterol for BPH (4 RCTs, n=519) found significant improvement in urinary symptom scores (weighted mean difference -4.9 points on IPSS) and peak urinary flow rate (+3.91 mL/s) compared to placebo. The phytosterol fraction acts synergistically with free fatty acids in the complete extract. Beta-sitosterol also modulates inflammatory signaling in prostate tissue by inhibiting NF-kB activation and reducing prostaglandin E2 synthesis.
Fatty alcohols (long-chain aliphatic alcohols)
Long-chain fatty alcohols are minor but pharmacologically relevant components of the unsaponifiable fraction. They contribute to the overall anti-inflammatory and lipid-modulating effects of the extract. The unsaponifiable fraction (sterols + fatty alcohols) constitutes approximately 2-6% of the liposterolic extract but contributes disproportionately to bioactivity.
Flavonoids and polyphenols
Flavonoids are minor constituents of saw palmetto berries and are largely absent from the liposterolic extract (which selectively extracts lipophilic compounds). Their contribution to the clinical activity of standardized liposterolic saw palmetto extracts is therefore limited. However, in whole berry preparations (tinctures, decoctions), flavonoids may provide additional antioxidant and anti-inflammatory support. The pharmacological activity of saw palmetto is primarily attributed to its lipophilic constituents rather than its flavonoid content.
Polysaccharides and other constituents
Polysaccharides contribute immunomodulatory activity that may complement the anti-inflammatory effects of the lipophilic fraction. These constituents are present in whole berry preparations (tinctures, decoctions) but are not extracted by the lipophilic solvents used to prepare the standardized liposterolic extract. This represents a pharmacological difference between whole berry preparations and liposterolic extracts.
Herbal Actions
Saw palmetto has been historically classified as a urinary tract tonic and diuretic in the Eclectic and traditional herbal literature. The diuretic action is considered secondary to its primary effects on prostate tissue: by reducing prostate volume and relieving bladder outlet obstruction in BPH, saw palmetto improves urinary flow and reduces post-void residual volume, effectively restoring normal urinary elimination. This functional improvement in urine output -- rather than a direct renal tubular diuretic mechanism -- underlies the traditional classification as a diuretic. Clinical trials consistently demonstrate improved peak urinary flow rate (Qmax) and reduced International Prostate Symptom Score (IPSS) encompassing urinary frequency, urgency, nocturia, and incomplete emptying.
[3, 6, 7]Potent anti-inflammatory activity mediated through multiple pathways: (1) inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis in prostate tissue; (2) inhibition of 5-lipoxygenase (5-LOX), reducing leukotriene B4 production; (3) inhibition of NF-kB nuclear translocation, a master regulator of inflammatory gene expression; (4) reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in prostate tissue. The anti-inflammatory action is considered central to the clinical efficacy of saw palmetto in BPH and lower urinary tract symptoms (LUTS), as chronic prostatic inflammation is increasingly recognized as a driver of BPH progression. Biopsy studies in men treated with saw palmetto extract show reduced inflammatory infiltrates in prostate tissue compared to baseline.
[3, 14, 18]Immunomodulatory effects of saw palmetto include modulation of inflammatory cell infiltration in prostate tissue, regulation of cytokine balance (shifting from pro-inflammatory Th1/Th17 toward regulatory profiles), and effects on complement activation. Polysaccharides from whole berry preparations demonstrate macrophage-stimulating activity in vitro. The clinical significance is most apparent in BPH, where histological studies show that saw palmetto extract reduces lymphocytic and macrophage infiltration in prostate stroma and epithelium. Saw palmetto's immunomodulatory effects distinguish it from purely anti-inflammatory agents and may contribute to its long-term benefits in chronic prostate conditions.
[14, 20]Saw palmetto's most pharmacologically distinctive action is the inhibition of 5-alpha-reductase, the enzyme that converts testosterone to the more potent androgen dihydrotestosterone (DHT). DHT is the primary hormonal driver of prostate growth and androgenetic alopecia. Saw palmetto inhibits both type I and type II 5-alpha-reductase isoforms in vitro (compared to finasteride, which primarily inhibits type II). Additional anti-androgenic mechanisms include: competitive inhibition of DHT binding to the androgen receptor, and inhibition of DHT-induced prostate cell proliferation. The magnitude of in vivo 5-alpha-reductase inhibition by saw palmetto is less than that achieved by pharmaceutical 5-alpha-reductase inhibitors (finasteride, dutasteride), which partly explains the different side-effect profile (saw palmetto does not significantly reduce serum PSA or cause sexual side effects at the same rate as finasteride).
[3, 13, 14]Relieves smooth muscle spasm
Mild antispasmodic activity on bladder detrusor muscle and urethral smooth muscle, contributing to improvement of irritative LUTS (urgency, frequency). The mechanism involves modulation of muscarinic receptor activity and calcium channel effects on smooth muscle. This action contributes to the symptomatic relief of overactive bladder symptoms that frequently co-exist with BPH.
[20]Saw palmetto extract inhibits proliferation of prostate epithelial cells and induces apoptosis in vitro. Mechanisms include down-regulation of growth factors (epidermal growth factor, insulin-like growth factor), inhibition of the PI3K/Akt signaling pathway, and promotion of apoptotic pathways. Clinical biopsy studies (Marks et al. 2000) demonstrated reduced prostate epithelial contraction in men treated with saw palmetto, though the clinical magnitude of anti-proliferative effects is debated. The anti-proliferative action is relevant to BPH management and has generated interest in potential chemopreventive applications, though evidence for cancer prevention remains preclinical.
[13, 14]Therapeutic Indications
Urinary System
Benign prostatic hyperplasia (BPH)
The most extensively studied and clinically validated indication for saw palmetto. BPH affects approximately 50% of men aged 51-60 and up to 90% of men over 80. Saw palmetto liposterolic extract has been evaluated in over 30 randomized controlled trials. The Cochrane review by Tacklind et al. (2012, updated from Wilt et al. 2002) analyzed 32 RCTs involving 5666 men. Earlier trials (particularly using the Permixon brand) showed significant improvements in IPSS scores, nocturia, and peak urinary flow rate. However, the STEP trial (Bent et al. 2006), a large rigorous RCT (n=225), found no significant difference between saw palmetto 160 mg bid and placebo for AUASI score at 12 months. The updated Cochrane review concluded that saw palmetto was not superior to placebo for LUTS/BPH. Importantly, the Permixon studies and STEP trial used different extracts, raising questions about extract equivalence. The CAMUS trial (Barry et al. 2011) escalated doses to 960 mg/day with no benefit over placebo. Despite mixed clinical trial results, saw palmetto remains the most widely used phytotherapy for BPH worldwide and has well-established traditional use status from EMA. The discrepancy between earlier positive European trials and later negative American trials may relate to differences in extract quality, standardization, patient populations, and outcome measures.
[3, 6, 7, 8, 9]Lower urinary tract symptoms (LUTS) associated with BPH
LUTS encompasses the obstructive (hesitancy, weak stream, intermittency, incomplete emptying) and irritative (frequency, urgency, nocturia) urinary symptoms caused by prostatic enlargement. Saw palmetto has traditional herbal medicinal product status from EMA for 'relief of lower urinary tract symptoms related to benign prostatic hyperplasia after serious conditions have been excluded.' Multiple earlier RCTs demonstrated improvements in individual LUTS parameters: nocturia (mean reduction 0.7-1.3 episodes/night), urinary frequency, and subjective symptom scores. The magnitude of symptomatic improvement in positive trials is clinically meaningful, even if the STEP and CAMUS trials did not replicate these findings. Patient satisfaction and quality of life measures have been positive in some trials.
[3, 6, 7]Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS)
NIH category III prostatitis (chronic pelvic pain syndrome) is a common condition in men under 50 for which treatment options are limited. Several small clinical trials have evaluated saw palmetto for CP/CPPS with mixed results. Reissigl et al. (2004) reported improvement in NIH-CPSI pain scores with Permixon. A pilot RCT combining saw palmetto with quercetin and other agents showed symptom improvement. The anti-inflammatory and immunomodulatory actions of saw palmetto provide pharmacological rationale for this indication. Larger, adequately powered trials are needed.
[14, 20]Reproductive System
Androgenetic alopecia (male pattern hair loss)
Androgenetic alopecia (AGA) is driven by DHT-mediated miniaturization of hair follicles. Given saw palmetto's 5-alpha-reductase inhibitory activity, it has been investigated as a natural alternative to finasteride for AGA. Rossi et al. (2012) RCT (n=100 men with mild-to-moderate AGA) compared saw palmetto 320 mg/day with finasteride 1 mg/day for 2 years: 38% of saw palmetto patients showed increased hair density (vs. 68% for finasteride). Prager et al. (2002) RCT (n=26) found that a topical saw palmetto formulation significantly improved hair growth at 5 months. While less effective than finasteride, saw palmetto is better tolerated (no sexual side effects reported in hair loss trials) and represents a reasonable option for men who decline pharmaceutical 5-alpha-reductase inhibitors. Additional studies using oral and topical formulations have shown modest but consistent trends toward hair count improvement.
[16, 17]Reproductive tonic and tissue builder (traditional use in men)
The Eclectic physicians used saw palmetto extensively as a reproductive tonic for men, describing it as a 'nutritive tonic to the reproductive organs.' Specific Eclectic indications included testicular atrophy, prostatic enlargement, chronic epididymitis, impotence, and loss of libido. Felter and Lloyd (King's American Dispensatory, 1898) described it as building up wasted tissue and 'fattening' the reproductive organs. This traditional application predates the modern understanding of 5-alpha-reductase inhibition but aligns with the pharmacological profile of nourishing, hormonal-modulating activity.
[19, 20]Reproductive and hormonal support in women (traditional)
Eclectic physicians also used saw palmetto in women for conditions including ovarian pain, mammary gland atrophy or tenderness, hirsutism, and polycystic ovary syndrome (PCOS) symptoms. The anti-androgenic mechanism provides theoretical support for use in female hyperandrogenism conditions. However, clinical trial evidence in women is essentially absent, and modern use in women is based primarily on traditional practice and mechanistic reasoning. Some naturopathic practitioners use saw palmetto as part of combination protocols for PCOS and hormonal acne in women.
[19, 20]Endocrine System
5-alpha-reductase-mediated conditions (general anti-androgenic support)
Saw palmetto's inhibition of 5-alpha-reductase has potential applications beyond BPH and alopecia. Conditions driven by excess DHT activity include acne vulgaris, seborrhea, and hirsutism. Some clinical and anecdotal evidence supports use for hormonal acne. The anti-androgenic effect is milder than pharmaceutical inhibitors, with correspondingly fewer hormonal side effects. Saw palmetto does not significantly reduce serum testosterone, PSA, or sex hormone-binding globulin at standard doses, distinguishing it from finasteride and dutasteride.
[3, 14]Energetics
Temperature
warm
Moisture
moist
Taste
Tissue States
cold/depression, atrophy, dry/atrophy
In Western energetic terms, saw palmetto is a warm, nourishing, moistening tonic directed primarily at the reproductive and urinary systems. Its oily, building quality reflects the high lipid content of the berries. Energetically classified as a trophorestorative for the reproductive organs, particularly in conditions of tissue wasting, atrophy, and debility of the genitourinary tract. The Eclectic physicians described it as a 'tissue builder' and nutritive tonic that 'fattens' and restores wasted tissues. This building, anabolic quality aligns with its anti-androgenic activity, as it was traditionally used for conditions of reproductive depletion in both men and women. In Ayurvedic terms (by analogy, as saw palmetto is not a traditional Ayurvedic herb), the warm, oily, nourishing quality would be described as reducing Vata (the principle of depletion, dryness, and wasting) and supporting Kapha (the principle of nourishment and structure). Matthew Wood describes saw palmetto as indicated for the 'thin, dried-up, wasted person with urinary irritation and reproductive weakness,' emphasizing its restorative, building energetics.
Traditional Uses
Seminole Nation and Indigenous Peoples of the Southeastern United States
- Berries consumed as a staple food source by the Seminole, Miccosukee, and other southeastern Indigenous peoples
- Treatment of urinary and reproductive disorders in men
- Remedy for 'wasting diseases' and conditions of general debility
- Antiseptic and treatment for inflammation of mucous membranes
- Berries used as a source of nutrition during periods of scarcity
"The Seminole Nation of Florida and other Indigenous peoples of the southeastern United States used saw palmetto berries as both food and medicine for centuries before European contact. The berries were an important seasonal food source, eaten fresh, dried, or prepared as a warm drink. Medicinal use included treatment of urinary difficulties, reproductive weakness, and general debility. European settlers and early American physicians learned of the plant's medicinal properties through contact with Indigenous communities. The transition from Indigenous to colonial medical use occurred in the mid-19th century as physicians noted the plant's effects on the urinary and reproductive systems."
Eclectic Medicine (19th-early 20th century American)
- Nutritive tonic and tissue builder for the reproductive organs in both sexes
- Treatment of prostatic enlargement (BPH) and chronic prostatitis
- Remedy for testicular atrophy, impotence, and loss of sexual desire
- Treatment for chronic cystitis, urethritis, and urinary irritability
- Tonic for 'wasting of the mammary glands' and ovarian dysfunction in women
- Expectorant and tonic for chronic bronchitis and respiratory catarrh
- General nutritive tonic for debilitated, thin, wasted patients
"The Eclectic physicians were the first Western medical practitioners to extensively document and popularize saw palmetto as a medicine. J.H. Hale introduced it in 1879 as a remedy for prostatic enlargement. Felter and Lloyd in King's American Dispensatory (1898) described saw palmetto as 'a tissue and nutrient tonic' with remarkable effects on the reproductive organs: 'it exerts a tissue-building force upon the organs it most affects... it is asserted to enlarge wasted organs as the mammae, ovaries, and testicles... its action appears to be that of the nutritive or tissue-building type.' The Eclectic indication picture emphasized saw palmetto for conditions of tissue wasting, atrophy, and debility -- particularly of the genitourinary system. They also valued it as a sedative to the urinary mucous membranes and as a respiratory tonic. The Eclectic classification of saw palmetto as a 'tissue builder' that restores wasted reproductive organs presaged the modern understanding of its hormonal-modulating activity."
European Phytotherapy (20th-21st century)
- First-line phytotherapy for symptomatic BPH / LUTS (particularly in Germany and France)
- Standardized liposterolic extract (Permixon) widely prescribed by urologists in France, Germany, Italy, and other European countries
- Alternative to watchful waiting in early BPH or as complementary therapy to alpha-blockers
- Treatment of nocturia and urinary frequency in men over 50
"Saw palmetto became the most widely used phytomedicine for BPH in Europe from the 1980s onward, particularly following the development and clinical testing of the standardized liposterolic extract Permixon (Pierre Fabre Medicament, France). In Germany, saw palmetto preparations were among the phytomedicines approved by Commission E for the treatment of BPH. In France and Italy, saw palmetto liposterolic extract is available by prescription and widely used by urologists as a first-line treatment for mild-to-moderate BPH. European clinical usage is based on extensive pharmacological characterization and dozens of clinical trials. The European tradition of phytomedicine provided the scientific framework for transforming a traditional American remedy into a rigorously studied and widely prescribed pharmaceutical product."
Modern Research
Cochrane review of Serenoa repens for benign prostatic hyperplasia
Updated Cochrane systematic review of 32 randomized controlled trials involving 5666 men, evaluating saw palmetto extracts (predominantly Permixon and other liposterolic extracts) versus placebo or active comparators for the treatment of LUTS associated with BPH.
Findings: The updated review found that Serenoa repens, when compared to placebo, did not significantly improve total IPSS scores (mean difference -0.88, 95% CI -1.97 to 0.20), peak urinary flow rate (Qmax), or prostate size. In comparisons with finasteride, saw palmetto produced similar improvements in urinary symptom scores, though finasteride more effectively reduced prostate volume. Saw palmetto was associated with fewer adverse effects than finasteride (no differences in sexual function, PSA levels unaffected). The review noted significant heterogeneity between studies and differences in extract quality.
Limitations: Significant heterogeneity between earlier positive European trials and later negative North American trials. Different extracts used across trials (Permixon, Prostasan, others) complicate pooled analysis. Standardization differences may affect bioequivalence. The negative STEP trial heavily influenced the overall conclusions. Outcome measures varied between studies. Some earlier trials had methodological limitations.
[7]
STEP trial: saw palmetto for BPH (Bent et al. 2006)
The Saw Palmetto Treatment for Enlarged Prostates (STEP) trial. Randomized, double-blind, placebo-controlled trial of 225 men aged 49+ with moderate-to-severe BPH symptoms (AUASI score 8+). Participants received saw palmetto extract 160 mg bid (a non-Permixon commercial preparation) or placebo for 12 months.
Findings: No significant difference between saw palmetto and placebo for the primary outcome (change in AUASI score: -0.68 vs. -0.72, P=0.92). No significant differences in secondary outcomes including peak urinary flow rate, post-void residual volume, prostate size (by ultrasound), PSA levels, or quality of life. The saw palmetto group had no significant increase in sexual dysfunction or other adverse effects compared to placebo.
Limitations: Used a single specific saw palmetto extract (not Permixon or other European pharmaceutical products); extract equivalence to Permixon is uncertain. Some critics have argued the extract used may have been of insufficient quality. Relatively short duration (12 months). Enrolled men with more severe symptoms than some positive European trials. The study has been criticized by proponents of saw palmetto for not using the most well-characterized extract.
[8]
CAMUS trial: dose-escalation of saw palmetto (Barry et al. 2011)
The Complementary and Alternative Medicine for Urological Symptoms (CAMUS) trial. Randomized, double-blind, placebo-controlled dose-escalation trial in 369 men with LUTS/BPH. Participants received saw palmetto extract (ethanolic extract, Prosta-Urgenin Uno) starting at 320 mg/day, escalating to 640 mg/day at 24 weeks and 960 mg/day at 48 weeks, or matching placebo, for a total of 72 weeks.
Findings: At no dose level did saw palmetto produce a statistically significant improvement over placebo in the primary outcome (AUASI score). At 72 weeks, the mean change in AUASI was -2.20 for saw palmetto vs. -2.99 for placebo (adjusted mean difference 0.79, 95% CI -0.90 to 2.47, P=0.36). No significant differences in peak urinary flow rate, post-void residual volume, prostate size, PSA, or quality of life at any dose. No significant adverse effects at any dose, including the supratherapeutic 960 mg/day dose.
Limitations: Used an ethanolic extract rather than the hexane-based liposterolic extract used in most positive European trials. Extract bioequivalence to Permixon is uncertain. The dose-escalation design meant patients at the highest dose level had been on treatment for 72 weeks, potentially diluting the treatment effect if response is dose-dependent from initiation. The excellent safety profile at 3x the standard dose is reassuring but limits interpretation of efficacy.
[9]
Permixon (hexane liposterolic extract) clinical studies
Permixon (Pierre Fabre Medicament) is a hexane liposterolic extract of S. repens standardized to 85-95% fatty acids and sterols. It is the most extensively studied individual saw palmetto product, with over 20 clinical trials and post-marketing surveillance data from millions of patient-years of use in Europe.
Findings: A systematic review and meta-analysis of Permixon trials (Boyle et al. 2004) concluded that Permixon significantly improved peak urinary flow rate (+2.75 mL/s, 95% CI 1.41-4.09) and reduced nocturia (-1.01 episodes/night, 95% CI -1.47 to -0.55) compared to placebo. The Permixon-specific evidence base is generally more positive than the broader saw palmetto evidence base, which includes trials using non-Permixon products. Head-to-head trials comparing Permixon with finasteride (Carraro et al. 1996, n=1098) and tamsulosin (Debruyne et al. 2002, n=811) showed similar efficacy for symptom improvement with better tolerability for Permixon. These trials raise the possibility that extract quality and extraction method are critical determinants of clinical efficacy.
Limitations: Many Permixon trials were sponsored by the manufacturer. Head-to-head comparator trials were non-inferiority designs with limitations. The question of whether Permixon's results can be generalized to other saw palmetto extracts remains unresolved. Publication bias may favor positive Permixon trials.
5-alpha-reductase inhibition: mechanism of action studies
In vitro and in vivo pharmacological studies characterizing saw palmetto's inhibition of 5-alpha-reductase and anti-androgenic mechanisms.
Findings: Saw palmetto liposterolic extract inhibits both type I and type II 5-alpha-reductase isoforms in vitro in a noncompetitive, dose-dependent manner. Inhibitory activity resides primarily in the free fatty acid fraction, with lauric acid, oleic acid, and myristic acid showing the greatest inhibitory potency. The extract also competitively inhibits DHT binding to the androgen receptor. Marks et al. (2001) prostate biopsy study: men treated with saw palmetto 160 mg bid for 6 months showed a significant decrease in DHT levels in prostate epithelial tissue (32% reduction vs. baseline, P=0.005) without significant changes in serum testosterone, PSA, or prostate size. This demonstrated in vivo 5-alpha-reductase inhibition at the tissue level.
Limitations: The magnitude of in vivo 5-alpha-reductase inhibition is substantially less than that achieved by finasteride (which reduces intraprostatic DHT by approximately 80%). In vitro inhibition concentrations may not reflect achievable tissue concentrations. The clinical significance of a 32% tissue DHT reduction (vs. finasteride's 80% reduction) for BPH symptom improvement is debated.
Saw palmetto for androgenetic alopecia
Clinical studies evaluating oral and topical saw palmetto for male androgenetic alopecia (male pattern hair loss) as an alternative to pharmaceutical 5-alpha-reductase inhibitors.
Findings: Rossi et al. (2012) randomized 100 men with mild-to-moderate AGA to saw palmetto 320 mg/day or finasteride 1 mg/day for 24 months. At study end, 38% of saw palmetto patients and 68% of finasteride patients showed increased hair density by blinded photographic assessment. Improvement with saw palmetto was predominantly in the vertex region. Prager et al. (2002) randomized 26 men to a topical saw palmetto + beta-sitosterol formulation or placebo; 60% of the active group showed improvement at 5 months (vs. 11% placebo). No sexual side effects were reported with saw palmetto in either study.
Limitations: Small sample sizes. Limited number of trials. Saw palmetto less effective than finasteride in the head-to-head comparison. Topical study used a combination product. Long-term efficacy data beyond 2 years are lacking. No studies comparing with dutasteride or minoxidil. The evidence base for this indication is substantially smaller than for BPH.
Preparations & Dosage
Standardized Extract
Strength: Liposterolic extract: drug-extract ratio approximately 10:1, containing 85-95% fatty acids and sterols. Hexane extraction (Permixon) or supercritical CO2 extraction are the standard methods. Ethanol extraction (Prostasan, CAMUS trial product) yields a different constituent profile with potentially different clinical efficacy.
Commercially prepared liposterolic (lipidic-sterol) extract of saw palmetto berries, obtained by hexane extraction or supercritical CO2 extraction. The reference product is Permixon (Pierre Fabre Medicament, France), a hexane extract standardized to contain 85-95% fatty acids and sterols. Other well-characterized products include Prostasan (ethanolic extract, Bioforce) and Prostagutt (combination with nettle root, Dr. Willmar Schwabe). Available as soft gel capsules containing the oily extract.
320 mg/day of liposterolic extract, taken as 160 mg twice daily or 320 mg once daily. This is the standard dose used in the majority of clinical trials. The CAMUS trial demonstrated safety at doses up to 960 mg/day, though no additional efficacy was demonstrated at higher doses.
Once or twice daily, preferably with meals (food enhances absorption of lipophilic constituents)
Minimum 4-6 weeks for initial assessment. Clinical trials typically demonstrate benefits at 8-24 weeks. Long-term use (months to years) is typical for chronic BPH management. EMA monograph recommends medical consultation if symptoms persist or worsen after 4 weeks.
Not indicated. BPH and other primary indications do not occur in children.
The standardized liposterolic extract is the preparation with the strongest clinical evidence. NOT ALL SAW PALMETTO PRODUCTS ARE EQUIVALENT. The extraction solvent (hexane vs. ethanol vs. supercritical CO2), drug-extract ratio, and free fatty acid content vary significantly between commercial products. Studies comparing commercial products have demonstrated wide variation in fatty acid content and composition. ConsumerLab and other independent analyses have found that many commercial saw palmetto products do not meet label claims for fatty acid content. For clinical applications, use of a characterized, standardized extract with demonstrated quality is essential. The disparity between positive European Permixon trials and negative American trials using other extracts underscores the importance of product quality.
Tincture
Strength: 1:5 in 45-60% ethanol (dried berries)
Macerate dried saw palmetto berries in ethanol-water. Traditional preparation: 1:5 in 45-60% ethanol. The high lipid content of the berries requires a relatively strong alcohol to extract fatty acids and sterols. Coarsely grind or crush dried berries before maceration. Macerate for 4-6 weeks with regular agitation. Press and filter. The resulting tincture will be dark brown to olive-green with a characteristic oily, somewhat fatty taste.
2-4 mL, 3 times daily
3 times daily, preferably with or after meals
Continuous use for a minimum of 6-8 weeks; long-term use is traditional for prostate support
Not indicated
The tincture is the traditional preparation form used by Eclectic physicians and contemporary Western herbalists. While it extracts a broader range of constituents than the liposterolic extract (including polysaccharides, flavonoids, and water-soluble compounds in addition to lipids), the fatty acid concentration per dose is lower than in standardized liposterolic extracts. Most clinical trial evidence is based on liposterolic extracts rather than tinctures. However, the tincture form provides the full spectrum of berry constituents and is valued by practitioners who emphasize whole-plant preparations. Often combined in formula with nettle root (Urtica dioica radix), pygeum bark (Prunus africana), and other prostate-supportive herbs.
Decoction
Strength: 3-5 g dried crushed berries per 300-400 mL water
Add 1-2 teaspoons (approximately 3-5 g) of coarsely crushed dried saw palmetto berries to 300-400 mL of water. Bring to a gentle boil, then simmer covered for 15-20 minutes. The resulting decoction will be dark, slightly oily, and somewhat turbid. Strain and drink warm. The berries may be decocted a second time for a weaker preparation.
1 cup (240 mL), 2-3 times daily
2-3 times daily
Continuous long-term use is traditional
Not indicated
The decoction is a traditional preparation that extracts primarily water-soluble constituents (polysaccharides, organic acids, some phenolics) with limited extraction of the lipophilic fatty acid fraction that is considered primary for anti-prostatic activity. This preparation is less pharmacologically targeted than the liposterolic extract but provides the broader spectrum of berry constituents including immunomodulatory polysaccharides. Historically used by Indigenous peoples and early American settlers. Less commonly recommended in modern phytotherapy compared to standardized extracts or tinctures.
[20]
Capsule / Powder
Strength: Soft gel: typically 160 mg or 320 mg of liposterolic extract per capsule. Whole berry powder: typically 500-585 mg per capsule.
Commercially prepared soft gel capsules or hard capsules containing either liposterolic extract or dried whole berry powder. Soft gel capsules containing the liposterolic extract are the most clinically studied oral dosage form. Whole berry powder capsules are also available but provide a different (and lower) concentration of active lipophilic constituents per dose.
Liposterolic extract capsules: 320 mg/day (as single dose or divided 160 mg bid). Whole berry powder capsules: 1-2 g daily in divided doses (less evidence-based than liposterolic extract).
Once or twice daily with food
Long-term continuous use for BPH; minimum 4-6 weeks for initial assessment
Not indicated
Soft gel capsules containing liposterolic extract are the most convenient and clinically validated dosage form. Taking with a fat-containing meal enhances absorption. Many commercial products combine saw palmetto with other ingredients (pygeum, beta-sitosterol, zinc, lycopene, nettle root) in prostate health formulations. Quality varies significantly between manufacturers. Look for products that specify the extraction method and guarantee fatty acid content (minimum 85-95% fatty acids and sterols for liposterolic extracts).
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Rare. Allergic reactions to saw palmetto are very uncommon. Patients with known allergy to palm-derived products should exercise caution.
Not indicated for children. The primary indications (BPH, LUTS, androgenetic alopecia) are adult conditions. No safety data in pediatric populations. The anti-androgenic activity makes use in children and adolescents inadvisable.
Patients with prostate cancer, breast cancer, or other hormone-sensitive malignancies should consult their oncologist before using saw palmetto, as the anti-androgenic activity may theoretically interact with hormonal therapies. Saw palmetto does not significantly alter serum PSA, but its use in the context of prostate cancer screening should be disclosed to the monitoring physician.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Finasteride and dutasteride (5-alpha-reductase inhibitors) (5-alpha-reductase inhibitors) | theoretical | Both saw palmetto and pharmaceutical 5-alpha-reductase inhibitors reduce DHT production via the same enzymatic target. Theoretically additive anti-androgenic effects. However, saw palmetto's mechanism is noncompetitive and pharmacologically distinct from finasteride (competitive type II inhibitor) and dutasteride (competitive type I and II inhibitor). |
| Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel, DOACs) (Anticoagulants / Antiplatelets) | theoretical | Rare case reports of bleeding events in saw palmetto users. Fatty acids may have mild antiplatelet activity via cyclooxygenase inhibition. One case report of intraoperative hemorrhage attributed to saw palmetto. |
| Oral contraceptives and hormone replacement therapy (Hormonal agents) | theoretical | Saw palmetto's anti-androgenic activity could theoretically interact with hormonal therapies that modulate the androgen-estrogen balance. No specific mechanism of pharmacokinetic interaction has been identified. |
| Alpha-adrenergic blockers (tamsulosin, doxazosin, alfuzosin) (Alpha-blockers for BPH) | minor | Both saw palmetto and alpha-blockers are used for LUTS/BPH. Different mechanisms of action (saw palmetto: anti-androgenic/anti-inflammatory; alpha-blockers: smooth muscle relaxation). Potential additive symptomatic improvement. |
Pregnancy & Lactation
Pregnancy
contraindicated
Lactation
contraindicated
Pregnancy: CONTRAINDICATED. Saw palmetto's anti-androgenic activity (5-alpha-reductase inhibition) poses a theoretical risk of feminization of a male fetus, analogous to the known teratogenic risk of finasteride. No human pregnancy data exist. Animal reproductive toxicity studies are limited. The anti-androgenic mechanism provides a strong theoretical basis for avoiding saw palmetto during pregnancy. Women of childbearing age should use contraception if taking saw palmetto. Lactation: CONTRAINDICATED due to insufficient data and theoretical risk from anti-androgenic constituents that may be excreted in breast milk. The primary clinical indications for saw palmetto (BPH, male pattern hair loss) are male conditions, making pregnancy and lactation exposure scenarios uncommon but not impossible (e.g., women using saw palmetto for hirsutism or PCOS).
Adverse Effects
References
Monograph Sources
- [1] German Commission E (Bundesinstitut fur Arzneimittel und Medizinprodukte). Commission E Monograph: Sabalis serrulatae fructus (Saw Palmetto Berry) -- Positive. Bundesanzeiger (Federal Gazette) (1993)
- [2] European Scientific Cooperative on Phytotherapy (ESCOP). ESCOP Monographs: Sabalis serrulatae fructus (Sabal Fruit). ESCOP Monographs, 2nd edition. Thieme, Stuttgart (2003)
- [3] Committee on Herbal Medicinal Products (HMPC), European Medicines Agency. European Union herbal monograph on Serenoa repens (W.Bartram) Small, fructus. European Medicines Agency (2015)
- [4] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Fructus Serenoae Repentis. World Health Organization, Geneva (2009)
- [5] National Center for Complementary and Integrative Health (NCCIH). Saw Palmetto. NCCIH, National Institutes of Health (2020)
Clinical Studies
- [6] Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (2002) ; 3 : CD001423 . DOI: 10.1002/14651858.CD001423 . PMID: 12137626
- [7] Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (2012) ; 12 : CD001423 . DOI: 10.1002/14651858.CD001423.pub3 . PMID: 23235581
- [8] Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. N Engl J Med (2006) ; 354 : 557-566 . DOI: 10.1056/NEJMoa053085 . PMID: 16467543
- [9] Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT; CAMUS Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) ; 306 : 1344-1351 . DOI: 10.1001/jama.2011.1364 . PMID: 21954478
- [10] Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int (2004) ; 93 : 751-756 . DOI: 10.1111/j.1464-410X.2003.04735.x . PMID: 15049985
- [11] Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Lamber DG, Delos S, Geurts-Moespot A, Debruyne FM, Vinet R. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate (1996) ; 29 : 231-240 . DOI: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E . PMID: 8876706
- [12] Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol (2002) ; 41 : 497-506 . DOI: 10.1016/S0302-2838(02)00066-2 . PMID: 12074792
- [13] Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology (2001) ; 57 : 999-1005 . DOI: 10.1016/S0090-4295(01)00949-5 . PMID: 11337315
- [14] Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis (2005) ; 8 : 151-157 . DOI: 10.1038/sj.pcan.4500797 . PMID: 15711607
- [15] Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev (1999) ; 3 : CD001043 . DOI: 10.1002/14651858.CD001043 . PMID: 10796740
- [16] Rossi A, Mari E, Scarno M, Garelli V, Maxia C, Perrone E, Palese E, Carlesimo M. Comparitative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol (2012) ; 25 : 1167-1173 . DOI: 10.1177/039463201202500435 . PMID: 23298508
- [17] Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med (2002) ; 8 : 143-152 . DOI: 10.1089/acm.2002.8.143 . PMID: 12006122
- [18] Suzuki M, Ito Y, Fujino T, Abe M, Sugiyama K, Nishi H, Sato H. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin (2009) ; 30 : 271-281 . DOI: 10.1038/aps.2009.1 . PMID: 19262550
Traditional Texts
- [19] Felter HW, Lloyd JU. King's American Dispensatory (18th edition, 3rd revision). Ohio Valley Company, Cincinnati (1898)
- [20] Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone/Elsevier (2013)
- [21] Bennett BC, Hicklin JR. Uses of saw palmetto (Serenoa repens, Arecaceae) in Florida. Econ Bot (2001) ; 52 : 381-393 . DOI: 10.1007/BF02862068
Pharmacopeias & Reviews
- [22] European Directorate for the Quality of Medicines (EDQM). European Pharmacopoeia Monograph: Saw Palmetto Fruit -- Sabalis serrulatae fructus. European Pharmacopoeia, 9th edition (2017)
- [23] United States Pharmacopoeial Convention. USP-NF Monograph: Saw Palmetto / Powdered Saw Palmetto / Saw Palmetto Extract. United States Pharmacopeia-National Formulary (2020)
Last updated: 2026-02-26 | Status: review